Rasmus Damtoft Siersbæk
Associate Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (7)
Background Despite promising preclinical studies, the application of DNA methyltransferase inhibitors in treating patients with solid cancers has thus far produced only modest outcomes. The presence of intratumoral heterogeneity in response to DNA methyltransferase inhibitors could significantly influence clinical efficacy, yet our understanding of the single-cell response to these drugs in solid tumors remains very limited. Methods In this study, we used cancer/testis antigen genes as a model for methylation-dependent gene expression to examine the activity of DNA methyltransferase inhibitors and their potential synergistic effect with histone deacetylase inhibitors at the single-cancer cell level. The analysis was performed on breast cancer patient-derived xenograft tumors and cell lines, employing a comprehensive set of techniques, including targeted single-cell mRNA sequencing. Mechanistic insights were further gained through DNA methylation profiling and chromatin structure analysis. Results We show that breast cancer tumors and cell cultures exhibit a highly heterogenous response to DNA methyltransferase inhibitors, persisting even under high drug concentrations and efficient DNA methyltransferase depletion. The observed variability in response to DNA methyltransferase inhibitors was independent of cancer-associated aberrations and clonal genetic diversity. Instead, these variations were attributed to stochastic demethylation of regulatory CpG sites and the DNA methylation-independent suppressive function of histone deacetylases. Conclusions Our findings point to intratumoral heterogeneity as a limiting factor in the use of DNA methyltransferase inhibitors as single agents in treatment of solid cancers and highlight histone deacetylase inhibitors as essential partners to DNA methyltransferase inhibitors in the clinic.
Year:
2025
Triple-negative breast cancer (TNBC) is a particularly aggressive subtype of breast cancer with high metastatic potential, limited treatment options, and low patient survival rates. By combining functional proteomic and genomic approaches, we identified an oncogenic transcriptional network in mesenchymal and invasive TNBC involving the glucocorticoid receptor, GATA6, MYC, and AP-1 transcription factors. Although these transcription factors bound extensively to shared enhancers, they utilized different enhancer repertoires from this shared enhancer pool to drive distinct downstream oncogenic pathways. The SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeling complex was a common gatekeeper of chromatin access for these transcription factors, and SWI/SNF inhibition decommissioned the distinct enhancer networks and protumorigenic gene programs they control. Consistently, SWI/SNF inhibition repressed TNBC proliferation, glucocorticoid-induced chemoresistance, and invasion in vitro and suppressed tumor growth and metastasis in vivo. Thus, these findings indicate that SWI/SNF-mediated chromatin remodeling drives TNBC progression, positioning SWI/SNF as a promising therapeutic target in this disease. Significance: Inhibition of SWI/SNF-mediated chromatin remodeling represses multiple cancer hallmarks in triple-negative breast cancer by blocking chromatin access for diverse transcription factors at shared enhancers, demonstrating the therapeutic potential of targeting DNA access.
Year:
2025
Year:
2025
Triple-negative breast cancer (TNBC) is a particularly aggressive subtype of breast cancer with high metastatic potential, limited treatment options, and low patient survival rates. By combining functional proteomic and genomic approaches, we identified an oncogenic transcriptional network in mesenchymal and invasive TNBC involving the glucocorticoid receptor, GATA6, MYC, and AP-1 transcription factors. Although these transcription factors bound extensively to shared enhancers, they utilized different enhancer repertoires from this shared enhancer pool to drive distinct downstream oncogenic pathways. The SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeling complex was a common gatekeeper of chromatin access for these transcription factors, and SWI/SNF inhibition decommissioned the distinct enhancer networks and protumorigenic gene programs they control. Consistently, SWI/SNF inhibition repressed TNBC proliferation, glucocorticoid-induced chemoresistance, and invasion in vitro and suppressed tumor growth and metastasis in vivo . Thus, these findings indicate that SWI/SNF-mediated chromatin remodeling drives TNBC progression, positioning SWI/SNF as a promising therapeutic target in this disease. Significance: Inhibition of SWI/SNF-mediated chromatin remodeling represses multiple cancer hallmarks in triple-negative breast cancer by blocking chromatin access for diverse transcription factors at shared enhancers, demonstrating the therapeutic potential of targeting DNA access.
Year:
2025
Year:
2024
Year:
2024
Year:
2023
Collaborators (10)
Robin Andersson
Associate Professor
University of Copenhagen
Adrian V. Lee
University of Pittsburgh
Steffi Oesterreich
UPMC Hillman Cancer Center
Mohammad Aarif Siddiqui
University of Southern Denmark
Jonathan R. Brewer
University of Southern Denmark
Henrik J. Ditzel
Professor, senior consultant, Head of Research
University of Southern Denmark
Paolo Ceppi
Associate Professor
University of Southern Denmark
Daniel D Brown
Senior Research Scientist
University of Pittsburgh
Mikkel Terp
Associate Professor
University of Southern Denmark
Ole N. Jensen
University of Southern Denmark
Make your next move.
Prepare your application
Review drafts before you send them.